DEC 12, 2017 10:00 AM PST

WEBINAR: Gold Standards and innovative processes for DC research in immuno-oncology

Sponsored by: Miltenyi Biotec
Speaker
  • R&D Manager: Dendritic Cell & B cells
    Biography
      Dr. Dzionek is an immunologist and serves as a head of R&D Reagents-Immunotherapy at Miltenyi Biotec GmbH. Dr. Dzionek completed his M.S. degree in Biology in the group of Prof. Andreas Radbruch in 1998 and earned his PhD in basic immunology from the University of Cologne in 2003. He is now working for more than 15 years in the field of dendritic cells focusing on the specific functions of different dendritic cell subsets. During his PhD thesis, he discovered and functionally characterized a number of blood dendritic cell specific receptors including BDCA‐1, 2, 3 and 4, which became a state of the art marker for human dendritic cell subsets. His work on BDCA‐2 at AmCell Corporation in Sunnyvale, CA and in the group of Marco Colonna and Marina Cella at Basel Institute for Immunology provided the basis for the clinical development of the BDCA‐2‐specific antibody for the use in interferon alpha driven autoimmune diseases, which is currently being tested under his supervision in the phase I clinical trial. His group at Miltenyi Biotec GmbH develops assays, tools and reagents for research and clinical‐scale separation and analysis of dendritic cells, B‐cells and tumor reactive T-cells.

    Abstract

    DATE: December 12, 2017
    TIME: 10:00AM PT

    Since their discovery, dendritic cells (DCs) have demonstrated a central role in the development of effective immune responses. Their unique ability to induce T cells responses to unknown antigens made them interesting research targets. However, DCs are not an easy cell type to study due to their low frequency in the periphery, lack of univocal lineage markers and the fact that they cannot be expanded in vitro. Artificial systems have been developed to obtain DC-like cells in numbers compatible with their study. The standard is to generate DCs from peripheral blood progenitors. This method has been instrumental in developing not only our basic understanding of these cells but also in translational aspects. Although the safety profile of DC approaches  has been proven in several trials and objective responses were observed, their study has been hindered by technical difficulties, especially in clinical settings. Recently, individual DCs subtypes have been shown to respond differently to specific pathogen and tumor environments and that they may functionally complement each other to evoke an effective immune response.
    The recent progress in immuno-oncology and the rapid development of new drugs, give us potential to design novel and effective combination strategies to contrast the complex tumor settings. DCs may be an invaluable part of approaches aiming at targeting several checkpoints of anti-tumoral immune responses. To facilitate translational studies with DCs we developed state of the art automated and closed processes to obtain clinical scale DCs, reagents produced under good manufacturing practice (GMP) and analysis tools. In this webinar we will illustrate the CliniMACS Prodigy LP-14 System for generation of monocyte-derived DCs and the innovative LP-BDC for isolation and activation of primary DCs to investigate their clinical potential.

    Learning Objectives:

    • Review recent progress in immuno-oncology
    • Review generation of monocyte-derived DCs 

     

    The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are manufactured and controlled under an ISO 13485-certified quality system. In the EU, the CliniMACS System components are available as CE-marked medical devices. In the US, the CliniMACS Prodigy LP-14 System is for research use only. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research only and not for therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, and MACS® are registered trademarks of Miltenyi Biotec GmbH. Copyright© 2017 Miltenyi BiotecPRO. All rights reserved.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 21, 2021 5:00 PM CEST
    APR 21, 2021 5:00 PM CEST
    Date: April 21, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Spatial Answers Trilogy - Spatial Answers in Immunology Immunology Researchers share their Spatial Discoveries in SARS-C...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    DEC 16, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    DEC 12, 2017 10:00 AM PST

    WEBINAR: Gold Standards and innovative processes for DC research in immuno-oncology

    Sponsored by: Miltenyi Biotec

    Specialty

    Cancer Research

    Immunology

    Cancer Therapeutics

    Molecular Biology

    Biotechnology

    Cancer Diagnostics

    Cell Biology

    Cell Culture

    Clinical Diagnostics

    Immuno-Oncology

    Clinical Research

    Molecular Diagnostics

    Biomarkers

    Genetics

    Oncology

    Geography

    North America58%

    Europe29%

    Asia6%

    South America4%

    Africa2%

    Oceania1%

    Registration Source

    Website Visitors100%

    Job Title

    Student13%

    Facility/Department Manager12%

    Executive11%

    Medical Laboratory Technician10%

    Scientist10%

    Research Scientist9%

    Educator/Faculty7%

    Clinical Laboratory Scientist7%

    Post Doc5%

    Lab Management5%

    Medical Doctor/Specialist5%

    QC/QA3%

    Marketing/Sales2%

    Consultant1%

    Biologist1%

    Organization

    Academic Institution13%

    Biotech Company12%

    Clinical Laboratory7%

    Hospital7%

    Research Institute4%

    Pharmaceutical Company4%

    Medical School4%

    Government2%

    Life Science Company2%

    Medical Center2%

    Consultant2%

    Ambulatory Care2%

    Non-Profit Organization1%

    Media1%

    Other4%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more